Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 372–373 (2008)Cite this article

Saag KG et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028–2039

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. van Staa TP et al. (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777–787

    Article  CAS  Google Scholar 

  2. Kanis JA et al. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19: 399–428

    Article  CAS  Google Scholar 

  3. Dalle Carbonare L et al. (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16: 97–103

    Article  CAS  Google Scholar 

  4. Kanis JA et al. (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11: iii–iv, ix–xi, 1–231

    Article  CAS  Google Scholar 

  5. Royal College of Physicians of London. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. [http://www.rcplondon.ac.uk/pubs/books/glucocorticoid/Glucocorticoid.pdf] (accessed 19 March 2008)

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Service of Bone Diseases, WHO Collaborating Center for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, University Hospitals and Faculty of Medicine, Rue Micheli-du-Crest 24, 1211 Geneva 14, Switzerland rene.rizzoli@medicine.unige.ch

Authors and Affiliations

  1. and Chairman of the Department of Rehabilitation and Geriatrics at the University Hospitals and Faculty of Medicine of Geneva, R Rizzoli is Professor of Medicine, Head of the Service of Bone Diseases (a WHO Collaborating Center for Osteoporosis Prevention), Switzerland.,

    René Rizzoli

Authors
  1. René Rizzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rizzoli, R. How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis?. Nat Rev Endocrinol 4, 372–373 (2008). https://doi.org/10.1038/ncpendmet0838

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0838

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing